Inspite of its delayed arrival Europe has a first-class opportunity to become a world-leader in the emerging global cannabis industry.
Back in June, FW corralled its database and publicly-available information to deliver a UK Cannabis Ecosystem which annotated the main players in a series of industry sub-sections.
Its approach to the European Medical Cannabis Ecosystem– publicly launched today – is to likewise identify its main players and sub-sectors, and highlight the opportunities in this rapidly-emerging industry.
Scepticism Over North American Model
Alastair Moore, Co-Founder of Hanway Associates, the creators of the First Wednesdays Network, says its latest piece of work highlights a different trajectory for the European industry to that of the North American forerunners.
And, it demonstrates how distinct European jurisdictions are using their innate advantages to carve out their own distinct sub-sector fiefdoms.
“The UK, like its European counterparts such as France and Germany, does look sceptically on what happened in North America and says ‘we can do that better, in more of a medical way’.
“The healthcare establishment is against cannabis sneaking-in by the back door; They want to see it done by the book, and head towards a pharmaceutically-led system.”
Around 150 Companies Feature In Ecosystem
With some 150 companies listed in nine sub-sectors, the First Wednesdays European ecosystem will provide a useful resource for anyone with an interest in the industry.
The sub-sectors run methodically from seed-to-sale, starting with Genetics and companies such as Seedsman, through to Cultivation, which includes the like of Bedrocan, Demecan and Emmac.
It then progresses up the the value-chain through Testing, Research and Extraction & Purification, which include the likes of Medicinal Genomics and Eurofins and on to Formulation & Manufacture and Branded Medicines which feature Cellen Therapeutics, Medalchemy, and Little Green Pharma, amongst others.
The final two categories are Technology and Distribution and these feature companies such as Shimadzu, Releaf, Faramko and Therismos.
Areas highlighted by FW as being under-developed and worthy of entrepreneurial attention include extraction and testing which are still generally wrapped in a vertically-integrated bubble – expect some developments in this space soon, said Mr Moore.
He also highlights the branded medicine cabinet as being one worthy of further attention.
With just a handful of medicines securing market authorisation, such as those from GW Pharmaceuticals, there is plethora of white-label suppliers in the market making it difficult for prescribers to settle on trustworthy brands, he believes.
Countries Picking Their Own Narratives
Individual nations are using their domestic capital to support the industry’s growth with Denmark developing a strong pharmaceutical cluster around Copenhagen.
Whilst in the UK, the lack of NHS prescriptions is driving competition and innovation in distribution – the final link in the ecosystem value chain.
Germany is also forging ahead in this space, whilst Portugal, with its favourable climate, is becoming a cultivation import and export hub.
While many had thought the cultivation sector would have been off-shored to the low-cost jurisdictions in Africa and Latin America it shows signs of resilience due to the the stable political and regulatory regimes in Europe.
The London Stock Exchange’s decision to look to list cannabis firms, and similar developments in Scandinavia, will attract capital to these destinations. “Countries are picking their own narratives.“ said Mr Moore.
Medical Cannabis Supply Chain Focus
Nevertheless, the Ecosystem leans towards elucidating on the supply chain, rather than focusing on individual countries.
Mr Moore said: “With the medical cannabis market we felt that would be the best way to do it. It starts with where the genetics are coming from, and how cultivation plays into the later stages; distribution, dispensing and branding products.
“We thought it would be an interesting way to see where, firstly the concentration of businesses are, and where innovation is happening and also to see where the next stage of opportunities are.
“We’re interested in how plant R&D, genetics and synthetic biology platforms earlier on in the supply chain, will make it better for patients and regulators at the other end, at the later stage of the supply chain.
“Some of the later stage supply chain stuff such as technology and data are really exciting.
“There are two areas which have been underfunded to date and that’s the genetics and research sub-sections, but, here in the UK and Europe we have the right academic institutions, life-science business parks, cannabinoid researchers to really do well and own this part of the value chain for Europe.”